The beneficial effects of rosuvastatin are independent of zinc supplementation in patients with atherosclerosis

dc.contributor.authorEvangelista, Karine Cavalcanti Maurício de Sena
dc.contributor.authorDias, Paula Cristina Silveira
dc.contributor.authorPaiva, Maria Sanali Moura de Oliveira
dc.contributor.authorFerreira, Diana Quitéria Cabral
dc.contributor.authorUrurahy, Marcela Abbott Galvão
dc.contributor.authorRezende, Adriana Augusto
dc.contributor.authorAbdalla, Dulcinéia Saes Parra
dc.contributor.authorPedrosa, Lucia Fatima Campos
dc.date.accessioned2024-08-26T23:12:14Z
dc.date.available2024-08-26T23:12:14Z
dc.date.issued2014-04
dc.description.resumoBackground: Statins have multiple antiatherosclerotic effects, but can reduce blood plasma concentrations of minerals, including zinc. As zinc possesses antiinflammatory and antioxidant effects, low zinc status can promote injuries or inadequate tissue repair in endothelial cells. Metallothionein (MT) expression might modulate responses induced by statins in patients with atherosclerosis. However, research regarding mineral status and the use of statins is scarce. This study evaluated the effects of zinc supplementation on zinc status and expression of the zinc-dependent MT1F and MT2A genes in patients with atherosclerosis treated with rosuvastatin. Methods: A double-blind, randomized clinical trial was performed with 54 participants treated with 10 mg rosuvastatin for 4 months with or without zinc supplementation (30 mg/day). Diet, lipid profile, high-sensitivity reactive protein C (hs-CRP), plasma and erythrocyte zinc concentrations, erythrocyte superoxide dismutase (SOD) activity, and MT1F and MT2A genes expression were analyzed before and after intervention. Results: Rosuvastatin therapy was effective in reducing low- and non-high-density lipoprotein, total cholesterol, triglycerides, and hs-CRP levels, independent of zinc supplementation. Additionally, zinc treatment had no effect on SOD enzyme activity (P = 0.201), plasma (P > 0.671) and erythrocyte (P > 0.123) zinc concentrations, or the pattern of MT1F and MT2A genes expression (P = 0.088 and P = 0.229, respectively). Conclusions: The effectiveness of rosuvastatin treatment is independent of the effects of zinc supplementation. Moreover, rosuvastatin treatment did not have a significant impact on zinc status or MT1F and MT2A genes expression in patients with atherosclerosispt_BR
dc.identifier.citationDIAS, Paula Cristina Silveira; EVANGELISTA, Karine Cavalcanti Mauricio Sena; PAIVA, Maria Sanali Moura de Oliveira; FERREIRA, Diana Quitéria Cabral; URURAHY, Marcela Abbott Galvão; REZENDE, Adriana Augusto; ABDALLA, Dulcinéia Saes Parra; PEDROSA, Lucia Fatima Campos. The beneficial effects of rosuvastatin are independent of zinc supplementation in patients with atherosclerosis. Journal of Trace Elements in Medicine and Biology, [S.l.], v. 28, n. 2, p. 194-199, abr. 2014. DOI: 10.1016/j.jtemb.2014.01.003. Disponível em: https://www.sciencedirect.com/science/article/pii/S0946672X14000066?via%3Dihub. Acesso em: 26 jul. 2024.pt_BR
dc.identifier.doihttp://dx.doi.org/10.1016/j.jtemb.2014.01.003
dc.identifier.urihttps://repositorio.ufrn.br/handle/123456789/59901
dc.languageenpt_BR
dc.publisherJournal of Trace Elements in Medicine and Biologypt_BR
dc.subjectAtherosclerosispt_BR
dc.subjectMetallothioneinpt_BR
dc.subjectRosuvastatinpt_BR
dc.subjectZinc supplementationpt_BR
dc.titleThe beneficial effects of rosuvastatin are independent of zinc supplementation in patients with atherosclerosispt_BR
dc.typearticlept_BR

Arquivos

Licença do Pacote

Agora exibindo 1 - 1 de 1
Nenhuma Miniatura disponível
Nome:
license.txt
Tamanho:
1.45 KB
Formato:
Item-specific license agreed upon to submission
Nenhuma Miniatura disponível
Baixar